Geode Capital Management LLC Raises Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Geode Capital Management LLC increased its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 3.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,326,504 shares of the company’s stock after buying an additional 336,629 shares during the quarter. Geode Capital Management LLC’s holdings in Teva Pharmaceutical Industries were worth $320,295,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Royal Palms Capital LLC purchased a new position in Teva Pharmaceutical Industries in the fourth quarter valued at about $3,553,000. Legal & General Group Plc raised its position in Teva Pharmaceutical Industries by 6.8% in the fourth quarter. Legal & General Group Plc now owns 3,608,387 shares of the company’s stock valued at $112,618,000 after purchasing an additional 228,189 shares during the period. Hantz Financial Services Inc. raised its position in Teva Pharmaceutical Industries by 71.8% in the fourth quarter. Hantz Financial Services Inc. now owns 37,388 shares of the company’s stock valued at $1,167,000 after purchasing an additional 15,620 shares during the period. Prospera Financial Services Inc raised its position in Teva Pharmaceutical Industries by 145.8% in the fourth quarter. Prospera Financial Services Inc now owns 163,246 shares of the company’s stock valued at $5,095,000 after purchasing an additional 96,845 shares during the period. Finally, Jefferies Financial Group Inc. purchased a new position in Teva Pharmaceutical Industries in the fourth quarter valued at about $461,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $34.51 on Tuesday. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. The business has a 50 day moving average of $32.45 and a two-hundred day moving average of $31.45. Teva Pharmaceutical Industries Ltd. has a 52 week low of $14.99 and a 52 week high of $37.35. The company has a market cap of $39.68 billion, a P/E ratio of 25.95, a PEG ratio of 3.60 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The company had revenue of $3.98 billion during the quarter. As a group, analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.36 EPS for the current year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 144,180 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $34.99, for a total value of $5,044,858.20. Following the completion of the transaction, the insider directly owned 80,760 shares in the company, valued at $2,825,792.40. The trade was a 64.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Richard Daniell sold 30,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total value of $1,062,000.00. Following the completion of the transaction, the executive vice president owned 55,755 shares of the company’s stock, valued at approximately $1,973,727. The trade was a 34.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 491,524 shares of company stock valued at $16,789,555 over the last 90 days. 0.54% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

TEVA has been the topic of several research reports. Barclays raised their price objective on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Wall Street Zen downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 2nd. JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Piper Sandler restated an “overweight” rating and set a $42.00 target price (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. Finally, Bank of America raised their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus price target of $41.78.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.